Cargando…

Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer

INTRODUCTION: Recent evidence suggests that microscopic lymph node metastases and circulating tumor cells may have clinical importance in lung cancer. The purpose of this study was to identify new molecular markers for tumor cells in regional lymph nodes (LNs) and peripheral blood (PB) from patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Nordgård, Oddmund, Singh, Gurpartap, Solberg, Steinar, Jørgensen, Lars, Halvorsen, Ann Rita, Smaaland, Rune, Brustugun, Odd Terje, Helland, Åslaug
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643953/
https://www.ncbi.nlm.nih.gov/pubmed/23671585
http://dx.doi.org/10.1371/journal.pone.0062153
_version_ 1782268405020098560
author Nordgård, Oddmund
Singh, Gurpartap
Solberg, Steinar
Jørgensen, Lars
Halvorsen, Ann Rita
Smaaland, Rune
Brustugun, Odd Terje
Helland, Åslaug
author_facet Nordgård, Oddmund
Singh, Gurpartap
Solberg, Steinar
Jørgensen, Lars
Halvorsen, Ann Rita
Smaaland, Rune
Brustugun, Odd Terje
Helland, Åslaug
author_sort Nordgård, Oddmund
collection PubMed
description INTRODUCTION: Recent evidence suggests that microscopic lymph node metastases and circulating tumor cells may have clinical importance in lung cancer. The purpose of this study was to identify new molecular markers for tumor cells in regional lymph nodes (LNs) and peripheral blood (PB) from patients with non-small cell lung cancer (NSCLC). METHODS: Candidate markers were selected based on digital transcript profiling and previous literature. KRT19, CEACAM5, EPCAM, DSG3, SFTPA, SFTPC and SFTPB mRNA levels were initially validated by real-time reverse transcription PCR-based quantification in 16 NSCLC tumors and 22 LNs and 12 PB samples from individuals without known cancer. Five of the candidate markers were selected for secondary validation by quantification in parallel tumor biopsies, regional LNs and PB samples from 55 patients undergoing surgery for NSCLC. LN and PB marker status were compared to clinicopathological patient data. RESULTS: All selected markers except DSG3 were present at high levels in the primary tumors and at very low or non-detectable levels in normal LNs and PB in the first round of validation, indicating a potential for detecting tumor cells in NSCLC patients. The expression profiles of KRT19, CEACAM5, DSG3, SFTPA and SFTPC mRNA were confirmed in the larger group during the secondary validation. Using the highest normal LN level of each marker as threshold, 39 (71%) of the 55 patients had elevated levels of at least one marker in regional LNs. Similarly, 26 (47%) patients had elevated levels of at least one marker in PB. A significantly higher number of patients with adenocarcinomas had positive LN status for these markers, compared with other histological types (P = 0.004). CONCLUSIONS: Several promising molecular tumor cell markers in regional LNs and PB were identified, including the new SFTPA and SFTPC mRNAs. Clinical follow-up in a larger cohort is needed to elucidate their prognostic value.
format Online
Article
Text
id pubmed-3643953
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36439532013-05-13 Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer Nordgård, Oddmund Singh, Gurpartap Solberg, Steinar Jørgensen, Lars Halvorsen, Ann Rita Smaaland, Rune Brustugun, Odd Terje Helland, Åslaug PLoS One Research Article INTRODUCTION: Recent evidence suggests that microscopic lymph node metastases and circulating tumor cells may have clinical importance in lung cancer. The purpose of this study was to identify new molecular markers for tumor cells in regional lymph nodes (LNs) and peripheral blood (PB) from patients with non-small cell lung cancer (NSCLC). METHODS: Candidate markers were selected based on digital transcript profiling and previous literature. KRT19, CEACAM5, EPCAM, DSG3, SFTPA, SFTPC and SFTPB mRNA levels were initially validated by real-time reverse transcription PCR-based quantification in 16 NSCLC tumors and 22 LNs and 12 PB samples from individuals without known cancer. Five of the candidate markers were selected for secondary validation by quantification in parallel tumor biopsies, regional LNs and PB samples from 55 patients undergoing surgery for NSCLC. LN and PB marker status were compared to clinicopathological patient data. RESULTS: All selected markers except DSG3 were present at high levels in the primary tumors and at very low or non-detectable levels in normal LNs and PB in the first round of validation, indicating a potential for detecting tumor cells in NSCLC patients. The expression profiles of KRT19, CEACAM5, DSG3, SFTPA and SFTPC mRNA were confirmed in the larger group during the secondary validation. Using the highest normal LN level of each marker as threshold, 39 (71%) of the 55 patients had elevated levels of at least one marker in regional LNs. Similarly, 26 (47%) patients had elevated levels of at least one marker in PB. A significantly higher number of patients with adenocarcinomas had positive LN status for these markers, compared with other histological types (P = 0.004). CONCLUSIONS: Several promising molecular tumor cell markers in regional LNs and PB were identified, including the new SFTPA and SFTPC mRNAs. Clinical follow-up in a larger cohort is needed to elucidate their prognostic value. Public Library of Science 2013-05-03 /pmc/articles/PMC3643953/ /pubmed/23671585 http://dx.doi.org/10.1371/journal.pone.0062153 Text en © 2013 Nordgård et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Nordgård, Oddmund
Singh, Gurpartap
Solberg, Steinar
Jørgensen, Lars
Halvorsen, Ann Rita
Smaaland, Rune
Brustugun, Odd Terje
Helland, Åslaug
Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title_full Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title_fullStr Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title_full_unstemmed Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title_short Novel Molecular Tumor Cell Markers in Regional Lymph Nodes and Blood Samples from Patients Undergoing Surgery for Non-Small Cell Lung Cancer
title_sort novel molecular tumor cell markers in regional lymph nodes and blood samples from patients undergoing surgery for non-small cell lung cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3643953/
https://www.ncbi.nlm.nih.gov/pubmed/23671585
http://dx.doi.org/10.1371/journal.pone.0062153
work_keys_str_mv AT nordgardoddmund novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT singhgurpartap novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT solbergsteinar novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT jørgensenlars novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT halvorsenannrita novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT smaalandrune novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT brustugunoddterje novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer
AT hellandaslaug novelmoleculartumorcellmarkersinregionallymphnodesandbloodsamplesfrompatientsundergoingsurgeryfornonsmallcelllungcancer